Not checkedNot checked for notices yet.
Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma
Liu Zhiyong, Gu Yanjun, Li Man and 4 more
Journal of Experimental & Clinical Cancer Research · 2008
doi:10.1186/1756-9966-27-60 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Aims</p> <p>To observe the effects of thalidomide on melanoma tumor growth and blood supply patterns in C57 mice.</p> <p>Methods</p> <p>Thirty mice inoculated subcutaneously with B16F10 cells were randomly divided into the treatment group and the control group. Thalidomide was administered once a day at a dose of 200 mg/kg for the treatment group starting on the fifth day after inoculation, and an equivalent volume of 0.5% carboxylmethyl cellulose was administered similarly in the control group. The diameter of the tumors was measured daily after inoculation until the mice were sacrificed on the 19th day. The different blood supply patterns were counted after immunohistochemical and PAS histochemical double-Staining. VEGF, NF-κB, PCNA, MMP-2 and MMP-9 expression in tumor tissue was also assessed.</p> <p>Results</p> <p>The tumor volume(<it>P </it>= 0.019) and the number of vasculogenic mimicry(<it>P </it>= 0.03) and mosaic vessels(<it>P </it>= 0.004) in the treatment group were significantly decreased compared with the control group. VEGF(<it>P </it>= 0.004), NF-κB(<it>P </it>= 0.009), PCNA(<it>P </it>= 0.002), MMP-2 (<it>P </it>= 0.000), MMP-9(<it>P </it>= 0.002) protein expression and MMP-2(<it>P </it>= 0.000) and MMP-9(<it>P </it>= 0.000) mRNA in the treatment group were significantly lower than those in the control groups.</p> <p>Conclusion</p> <p>Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in melanoma through the regulation of vasculogenic factors, and it can induce necrosis of melanoma cells, which may be related with the NF-κB signaling pathway.</p>
Abstract licence: CC BY
Cited by papers we hold4
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.